NIHR | Manchester Biomedical Research Centre
Our Research:

Cancer Precision Medicine

The North West has the second highest cancer incidence and includes 11 of England’s most deprived areas with disproportionate cancer prevalence. The NHS Long Term Plan is to diagnose 75% of cancers at stage one or two by 2028.

Our aim is to improve patient outcomes with enhanced cancer precision medicine.

Our research takes place at The Christie NHS Foundation Trust, Europe’s largest single-site cancer centre, UK’s first accredited comprehensive cancer centre and in Europe’s top three for early-phase drug development.

The Christie hosts the UK’s largest cell and gene therapy trials for solid tumours, is an Innovate UK Advanced Therapy Centre, part of the NIHR Manchester Clinical Research Facility and a CRUK/NIHR Experimental Cancer Medicine Centre. More than 25% of UK patients are referred to The Christie.

The Precision Medicine Theme contains the following programmes:

  • Expansion of UK precision medicine early phase trials
  • Personalising immunotherapy
  • Counteracting treatment resistance
  • Digital clinical trials with patients as co-researchers